VAM
UBX

Verity Asset Management’s Unity Biotechnology UBX Stock Holding History

Verity Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,198
Closed -$104K – 150
2020
Q2 		$104K Sell
1,198
-277
-19% -$20.5K 0.1% 123
2020
Q1 		$86K Buy
+1,475
New +$93K 0.11% 114

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verity Asset Management's UBX Position: Q3 2020 in Review

Verity Asset Management sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 1,198 shares — an estimated $104K sold.

Verity Asset Management first reported a position in UBX in Q1 2020 and held it in 2 quarters. The position peaked at $104K in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • Verity Asset Management reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Verity Asset Management sold 1,198 Unity Biotechnology shares in Q3 2020, an estimated $104K.
  • Verity Asset Management first reported a position in Unity Biotechnology in Q1 2020 and held it in 2 quarters.
  • Verity Asset Management's Unity Biotechnology position peaked at $104K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Verity Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.